{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T21:03:14Z","timestamp":1784322194539,"version":"3.55.0"},"reference-count":81,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.hoc.2025.04.007","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T15:53:39Z","timestamp":1747929219000},"page":"785-804","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Leiomyosarcoma Therapeutic Approaches and Future Directions"],"prefix":"10.1016","volume":"39","author":[{"given":"Candace L.","family":"Haddox","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"David J.","family":"Papke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9sar","family":"Serrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hoc.2025.04.007_bib1","series-title":"WHO Classification of Tumours Editorial Board","year":"2020"},{"issue":"6","key":"10.1016\/j.hoc.2025.04.007_bib2","doi-asserted-by":"crossref","first-page":"694","DOI":"10.3109\/0284186X.2012.689111","article-title":"Diagnosis and treatment of sarcoma of the uterus. A review","volume":"51","author":"Trop\u00e9","year":"2012","journal-title":"Acta Oncol"},{"issue":"12","key":"10.1016\/j.hoc.2025.04.007_bib3","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1007\/s00432-024-06033-5","article-title":"Comparing epidemiological and clinical data from RPS patients documented in a German cancer registry to a cohort from TARPSWG reference centres","volume":"150","author":"Neemann","year":"2024","journal-title":"J Cancer Res Clin Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2025.04.007_bib4","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3390\/jpm12030345","article-title":"Metastatic pattern of truncal and extremity leiomyosarcoma: retrospective analysis of predictors, outcomes, and detection","volume":"12","author":"Tigchelaar","year":"2022","journal-title":"J Pers Med"},{"key":"10.1016\/j.hoc.2025.04.007_bib5","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.suronc.2020.06.003","article-title":"A closer look at the natural history and recurrence patterns of high-grade truncal\/extremity leiomyosarcomas: a multi-institutional analysis from the US sarcoma collaborative","volume":"34","author":"Lee","year":"2020","journal-title":"Surg Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2025.04.007_bib6","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.3390\/ijms23042190","article-title":"Integrative genomic and transcriptomic profiling reveals a differential molecular signature in uterine leiomyoma versus leiomyosarcoma","volume":"23","author":"Machado-Lopez","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.hoc.2025.04.007_bib7","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1038\/s41379-022-01011-z","article-title":"A novel morphology-based risk stratification model for stage I uterine leiomyosarcoma: an analysis of 203 cases","volume":"35","author":"Chapel","year":"2022","journal-title":"Mod Pathol"},{"issue":"5","key":"10.1016\/j.hoc.2025.04.007_bib8","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/cncr.26390","article-title":"Sarcomas in TP53 germline mutation carriers: a review of the IARC TP53 database","volume":"118","author":"Ognjanovic","year":"2012","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.hoc.2025.04.007_bib9","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1093\/jnci\/djx235","article-title":"Risk of soft-tissue sarcoma among 69 460 five-year survivors of childhood cancer in Europe","volume":"110","author":"Bright","year":"2018","journal-title":"J Natl Cancer Inst"},{"issue":"20","key":"10.1016\/j.hoc.2025.04.007_bib10","doi-asserted-by":"crossref","first-page":"4780","DOI":"10.1158\/1078-0432.CCR-24-1160","article-title":"The impact of Li-Fraumeni and germline retinoblastoma mutations on leiomyosarcoma initiation, outcomes, and genetic testing recommendations","volume":"30","author":"Dermawan","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.hoc.2025.04.007_bib11","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.annonc.2022.07.008","article-title":"Comprehensive cancer predisposition testing within the prospective MASTER trial identifies hereditary cancer patients and supports treatment decisions for rare cancers","volume":"33","author":"Jahn","year":"2022","journal-title":"Ann Oncol"},{"issue":"6629","key":"10.1016\/j.hoc.2025.04.007_bib12","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1126\/science.abj4784","article-title":"Heritable defects in telomere and mitotic function selectively predispose to sarcomas","volume":"379","author":"Ballinger","year":"2023","journal-title":"Science"},{"key":"10.1016\/j.hoc.2025.04.007_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.104055","article-title":"Special features of sarcomas developed in patients with Lynch syndrome: a systematic review","volume":"188","author":"Poumeaud","year":"2023","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.hoc.2025.04.007_bib14","article-title":"Histology-specific prognostication for radiation-associated soft tissue sarcoma","volume":"6","author":"Bartlett","year":"2022","journal-title":"JCO Precis Oncol"},{"issue":"23","key":"10.1016\/j.hoc.2025.04.007_bib15","doi-asserted-by":"crossref","first-page":"5563","DOI":"10.3390\/cancers15235563","article-title":"A clinicopathology review and update of Epstein-Barr virus-associated mesenchymal tumors","volume":"15","author":"Lee","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.hoc.2025.04.007_bib16","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/his.12466","article-title":"Progressive loss of myogenic differentiation in leiomyosarcoma has prognostic value","volume":"66","author":"Demicco","year":"2015","journal-title":"Histopathology"},{"issue":"1","key":"10.1016\/j.hoc.2025.04.007_bib17","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1046\/j.1440-1827.2000.01001.x","article-title":"Immunohistochemical detection of cytokeratin and epithelial membrane antigen in leiomyosarcoma: a systematic study of 100 cases","volume":"50","author":"Iwata","year":"2000","journal-title":"Pathol Int"},{"issue":"1","key":"10.1016\/j.hoc.2025.04.007_bib18","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/RCT.0000000000001656","article-title":"Uterine sarcoma or degenerating fibroid? Validating the new consensus magnetic resonance imaging algorithm for evaluating atypical uterine masses","volume":"49","author":"Horowitz","year":"2025","journal-title":"J Comput Assist Tomogr"},{"issue":"7","key":"10.1016\/j.hoc.2025.04.007_bib19","doi-asserted-by":"crossref","first-page":"e282","DOI":"10.1002\/jmri.26630","article-title":"MRI screening for uterine leiomyosarcoma","volume":"49","author":"Tong","year":"2019","journal-title":"J Magn Reson Imaging"},{"issue":"2","key":"10.1016\/j.hoc.2025.04.007_bib20","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.211658","article-title":"MRI evaluation of uterine masses for risk of leiomyosarcoma: a consensus statement","volume":"306","author":"Hindman","year":"2023","journal-title":"Radiology"},{"key":"10.1016\/j.hoc.2025.04.007_bib21","series-title":"Female genital tumours","author":"Lokuhetty","year":"2020"},{"issue":"1","key":"10.1016\/j.hoc.2025.04.007_bib22","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/PAP.0000000000000478","article-title":"Risk stratification of uterine smooth muscle tumors: the role of morphology, immunohistochemistry, and molecular testing","volume":"32","author":"Momeni-Boroujeni","year":"2025","journal-title":"Adv Anat Pathol"},{"issue":"4","key":"10.1016\/j.hoc.2025.04.007_bib23","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.cell.2017.10.014","article-title":"Comprehensive and integrated genomic characterization of adult soft tissue sarcomas","volume":"171","year":"2017","journal-title":"Cell"},{"issue":"15","key":"10.1016\/j.hoc.2025.04.007_bib24","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1002\/cncr.33542","article-title":"Relationships between highly recurrent tumor suppressor alterations in 489 leiomyosarcomas","volume":"127","author":"Schaefer","year":"2021","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.hoc.2025.04.007_bib25","doi-asserted-by":"crossref","first-page":"3405","DOI":"10.1038\/s41467-022-30453-x","article-title":"Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets","volume":"13","author":"Nacev","year":"2022","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.hoc.2025.04.007_bib26","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41467-017-02602-0","article-title":"Integrative genomic and transcriptomic analysis of leiomyosarcoma","volume":"9","author":"Chudasama","year":"2018","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.hoc.2025.04.007_bib27","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1038\/s41467-020-16134-7","article-title":"The landscape of chromothripsis across adult cancer types","volume":"11","author":"Voronina","year":"2020","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.hoc.2025.04.007_bib28","doi-asserted-by":"crossref","first-page":"642","DOI":"10.3390\/genes11060642","article-title":"DNA replication stress and chromosomal instability: dangerous liaisons","volume":"11","author":"Wilhelm","year":"2020","journal-title":"Genes (Basel)"},{"issue":"3","key":"10.1016\/j.hoc.2025.04.007_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2024.167632","article-title":"Deep multi-omics integration approach reveals new molecular features of uterine leiomyosarcoma","volume":"1871","author":"Falcao","year":"2025","journal-title":"Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"},{"issue":"24","key":"10.1016\/j.hoc.2025.04.007_bib30","doi-asserted-by":"crossref","first-page":"5128","DOI":"10.1158\/1078-0432.CCR-23-0998","article-title":"Hyper-dependence on NHEJ enables synergy between DNA-PK inhibitors and low-dose doxorubicin in leiomyosarcoma","volume":"29","author":"Marino-Enriquez","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.hoc.2025.04.007_bib31","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1158\/1078-0432.CCR-24-0148","article-title":"Developing novel genomic risk stratification models in soft tissue and uterine leiomyosarcoma","volume":"30","author":"Dermawan","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.hoc.2025.04.007_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2024.100651","article-title":"Detection of alternative lengthening of telomeres via chromogenic in situ hybridization for the prognostication of panNETs and other neoplasms","volume":"38","author":"Heaphy","year":"2024","journal-title":"Mod Pathol"},{"issue":"1","key":"10.1016\/j.hoc.2025.04.007_bib33","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1200\/JCO.1998.16.1.197","article-title":"Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity","volume":"16","author":"Yang","year":"1998","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2025.04.007_bib34","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.prro.2021.04.005","article-title":"Radiation therapy for treatment of soft tissue sarcoma in adults: executive summary of an ASTRO clinical practice guideline","volume":"11","author":"Salerno","year":"2021","journal-title":"Pract Radiat Oncol"},{"issue":"12","key":"10.1016\/j.hoc.2025.04.007_bib35","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S1470-2045(22)00638-6","article-title":"Hypofractionated, 3-week, preoperative radiotherapy for patients with soft tissue sarcomas (HYPORT-STS): a single-centre, open-label, single-arm, phase 2 trial","volume":"23","author":"Guadagnolo","year":"2022","journal-title":"Lancet Oncol"},{"issue":"9092","key":"10.1016\/j.hoc.2025.04.007_bib36","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/S0140-6736(97)08165-8","article-title":"Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Sarcoma meta-analysis collaboration","volume":"350","year":"1997","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.hoc.2025.04.007_bib37","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/cncr.23592","article-title":"A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma","volume":"113","author":"Pervaiz","year":"2008","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.hoc.2025.04.007_bib38","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/S1470-2045(12)70346-7","article-title":"Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial","volume":"13","author":"Woll","year":"2012","journal-title":"The Lancet Oncology"},{"issue":"19","key":"10.1016\/j.hoc.2025.04.007_bib39","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1200\/JCO.19.03289","article-title":"Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: final results of a randomized trial from Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) sarcoma groups","volume":"38","author":"Gronchi","year":"2020","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2025.04.007_bib40","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.soc.2022.03.011","article-title":"Leiomyosarcoma: current clinical management and future horizons","volume":"31","author":"Devaud","year":"2022","journal-title":"Surg Oncol Clin N Am"},{"issue":"1","key":"10.1016\/j.hoc.2025.04.007_bib41","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jamcollsurg.2019.09.013","article-title":"Identifying the minimum volume threshold for retroperitoneal soft tissue sarcoma resection: merging national data with consensus expert opinion","volume":"230","author":"Villano","year":"2020","journal-title":"J Am Coll Surg"},{"issue":"10","key":"10.1016\/j.hoc.2025.04.007_bib42","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/S1470-2045(20)30446-0","article-title":"Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial","volume":"21","author":"Bonvalot","year":"2020","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.hoc.2025.04.007_bib43","doi-asserted-by":"crossref","first-page":"6886","DOI":"10.1245\/s10434-023-13933-2","article-title":"Neoadjuvant chemotherapy in retroperitoneal sarcoma: a national cohort study","volume":"30","author":"Tortorello","year":"2023","journal-title":"Ann Surg Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2025.04.007_bib44","doi-asserted-by":"crossref","first-page":"4573","DOI":"10.1245\/s10434-023-13500-9","article-title":"A randomized phase III study of neoadjuvant chemotherapy followed by surgery versus surgery alone for patients with high-risk retroperitoneal sarcoma (STRASS2)","volume":"30","author":"Lambdin","year":"2023","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2025.04.007_bib45","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ygyno.2017.02.012","article-title":"Prognosis and treatment of uterine leiomyosarcoma: a national cancer database study","volume":"145","author":"Seagle","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"33","key":"10.1016\/j.hoc.2025.04.007_bib46","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.18.00454","article-title":"Adjuvant gemcitabine plus docetaxel followed by doxorubicin versus observation for high-grade uterine leiomyosarcoma: a phase III NRG oncology\/gynecologic oncology group study","volume":"36","author":"Hensley","year":"2018","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2025.04.007_bib47","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1002\/cncr.27942","article-title":"Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005)","volume":"119","author":"Hensley","year":"2013","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.hoc.2025.04.007_bib48","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1200\/JCO.1985.3.9.1240","article-title":"A randomized clinical trial of adjuvant Adriamycin in uterine sarcomas: a gynecologic oncology group study","volume":"3","author":"Omura","year":"1985","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.hoc.2025.04.007_bib49","doi-asserted-by":"crossref","first-page":"5787","DOI":"10.3390\/jcm13195787","article-title":"The effect of surgical resection on cancer-specific mortality in pelvic soft tissue sarcoma according to histologic subtype and stage","volume":"13","author":"Piccinelli","year":"2024","journal-title":"J Clin Med"},{"issue":"11","key":"10.1016\/j.hoc.2025.04.007_bib50","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s11547-018-0912-5","article-title":"Stereotactic body radiotherapy for oligometastatic soft tissue sarcoma","volume":"123","author":"Loi","year":"2018","journal-title":"Radiol Med"},{"issue":"1","key":"10.1016\/j.hoc.2025.04.007_bib51","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.clon.2014.09.010","article-title":"Effect on survival of local ablative treatment of metastases from sarcomas: a study of the French sarcoma group","volume":"27","author":"Falk","year":"2015","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.hoc.2025.04.007_bib52","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.radonc.2020.01.010","article-title":"Stereotactic ablative radiation therapy for pulmonary metastases: improving overall survival and identifying subgroups at high risk of local failure","volume":"145","author":"Pasalic","year":"2020","journal-title":"Radiother Oncol"},{"issue":"15","key":"10.1016\/j.hoc.2025.04.007_bib53","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1002\/cncr.35330","article-title":"Safety and efficacy of percutaneous image-guided ablation for soft tissue sarcoma metastases to the liver","volume":"130","author":"Awad","year":"2024","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.hoc.2025.04.007_bib54","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s11912-024-01532-7","article-title":"Update on percutaneous ablation for sarcoma","volume":"26","author":"Parvinian","year":"2024","journal-title":"Curr Oncol Rep"},{"issue":"10","key":"10.1016\/j.hoc.2025.04.007_bib55","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S1470-2045(17)30622-8","article-title":"Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GEDDIS): a randomised controlled phase 3 trial","volume":"18","author":"Seddon","year":"2017","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.hoc.2025.04.007_bib56","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1002\/cncr.32795","volume":"126","author":"D'Ambrosio","year":"2020","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.hoc.2025.04.007_bib57","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/S1470-2045(17)30381-9","article-title":"Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406\/SARC021): an international, multicentre, open-label, randomised phase 3 trial","volume":"18","author":"Tap","year":"2017","journal-title":"Lancet Oncol"},{"issue":"13","key":"10.1016\/j.hoc.2025.04.007_bib58","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1001\/jama.2020.1707","article-title":"Effect of doxorubicin plus olaratumab vs doxorubicin plus placebo on survival in patients with advanced soft tissue sarcomas: the ANNOUNCE randomized clinical trial","volume":"323","author":"Tap","year":"2020","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.hoc.2025.04.007_bib59","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1056\/NEJMoa2403394","article-title":"Doxorubicin\u2013trabectedin with trabectedin maintenance in leiomyosarcoma","volume":"391","author":"Pautier","year":"2024","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.hoc.2025.04.007_bib60","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1634\/theoncologist.2011-0467","volume":"17","author":"Pautier","year":"2012","journal-title":"Oncologist"},{"issue":"19","key":"10.1016\/j.hoc.2025.04.007_bib61","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1200\/JCO.2006.10.4117","article-title":"Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of Sarcoma Alliance for Research through Collaboration study 002 [corrected]","volume":"25","author":"Maki","year":"2007","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.hoc.2025.04.007_bib62","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1200\/JCO.2010.33.6107","article-title":"Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study","volume":"29","author":"Garc\u00eda-Del-Muro","year":"2011","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.hoc.2025.04.007_bib63","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1002\/cncr.32117","article-title":"Overall survival and histology-specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma","volume":"125","author":"Patel","year":"2019","journal-title":"Cancer"},{"issue":"9829","key":"10.1016\/j.hoc.2025.04.007_bib64","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","article-title":"Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"379","author":"van der Graaf","year":"2012","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.hoc.2025.04.007_bib65","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1002\/cncr.20521","article-title":"Tissue microarray immunohistochemical expression of estrogen, progesterone, and androgen receptors in uterine leiomyomata and leiomyosarcoma","volume":"101","author":"Leitao","year":"2004","journal-title":"Cancer"},{"issue":"1B","key":"10.1016\/j.hoc.2025.04.007_bib66","first-page":"729","article-title":"Estrogen and progesterone receptor expression in patients with uterine leiomyosarcoma and correlation with different clinicopathological parameters","volume":"23","author":"Bodner","year":"2003","journal-title":"Anticancer Res"},{"key":"10.1016\/j.hoc.2025.04.007_bib67","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2013-202107","article-title":"Hormone dependency in metastatic low-grade leiomyosarcoma following uterine smooth muscle tumour of uncertain malignant potential","author":"Serrano","year":"2014","journal-title":"BMJ Case Rep"},{"issue":"3","key":"10.1016\/j.hoc.2025.04.007_bib68","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.ygyno.2021.09.010","article-title":"Phase 2 study of anastrozole in rare cohorts of patients with estrogen receptor\/progesterone receptor positive leiomyosarcomas and carcinosarcomas of the uterine corpus: the PARAGON trial (ANZGOG 0903)","volume":"163","author":"Edmondson","year":"2021","journal-title":"Gynecol Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2025.04.007_bib69","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/cncr.28476","article-title":"Phase 2 trial of aromatase inhibition with letrozole in patients with uterine leiomyosarcomas expressing estrogen and\/or progesterone receptors","volume":"120","author":"George","year":"2014","journal-title":"Cancer"},{"issue":"22","key":"10.1016\/j.hoc.2025.04.007_bib70","doi-asserted-by":"crossref","first-page":"4679","DOI":"10.1158\/1078-0432.CCR-23-0692","article-title":"Low-grade uterine leiomyosarcoma is highly sensitive to hormonal treatment","volume":"29","author":"Sanfilippo","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.hoc.2025.04.007_bib71","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.3390\/cancers15072099","article-title":"Targeting the molecular and immunologic features of leiomyosarcoma","volume":"15","author":"Cope","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/j.hoc.2025.04.007_bib72","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1158\/1078-0432.CCR-23-2250","article-title":"Phase II study of eribulin plus pembrolizumab in metastatic soft-tissue sarcomas: clinical outcomes and biological correlates","volume":"30","author":"Haddox","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.hoc.2025.04.007_bib73","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.3390\/cancers12071873","article-title":"A retrospective analysis of the efficacy of immunotherapy in metastatic soft-tissue sarcomas","volume":"12","author":"Monga","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.hoc.2025.04.007_bib74","doi-asserted-by":"crossref","DOI":"10.1200\/JCO-24-02524","article-title":"Botensilimab (Fc-enhanced anti-cytotoxic lymphocyte-association protein-4 antibody) plus balstilimab (anti-PD-1 antibody) in patients with relapsed\/refractory metastatic sarcomas","author":"Wilky","year":"2025","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.hoc.2025.04.007_bib75","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1158\/1078-0432.CCR-24-1037","article-title":"Safety and efficacy of the combination lurbinectedin plus doxorubicin from a phase 1b trial in patients with advanced\/metastatic soft-tissue sarcoma","volume":"30","author":"Cote","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"25","key":"10.1016\/j.hoc.2025.04.007_bib76","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.1200\/JCO.23.00402","article-title":"Phase II study of olaparib and temozolomide for advanced uterine leiomyosarcoma (NCI protocol 10250)","volume":"41","author":"Ingham","year":"2023","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.hoc.2025.04.007_bib77","doi-asserted-by":"crossref","first-page":"5122","DOI":"10.1158\/1078-0432.CCR-19-0206","article-title":"Arginine starvation and docetaxel induce c-myc-driven hent1 surface expression to overcome gemcitabine resistance in ASS1-negative tumors","volume":"25","author":"Prudner","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"15_suppl","key":"10.1016\/j.hoc.2025.04.007_bib78","doi-asserted-by":"crossref","first-page":"11508","DOI":"10.1200\/JCO.2021.39.15_suppl.11508","article-title":"Phase II trial of pegylated arginine deiminase in combination with gemcitabine and docetaxel for the treatment of soft tissue sarcoma","volume":"39","author":"Van Tine","year":"2021","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.hoc.2025.04.007_bib79","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1200\/JCO.23.01684","article-title":"Phase Ib study of unesbulin (PTC596) plus dacarbazine for the treatment of locally recurrent, unresectable or metastatic, relapsed or refractory leiomyosarcoma","volume":"42","author":"Van Tine","year":"2024","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2025.04.007_bib80","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1097\/PAS.0000000000001795","article-title":"Epithelioid leiomyosarcoma of the uterus: modern outcome-based appraisal of diagnostic criteria in a large institutional series","volume":"46","author":"Chapel","year":"2022","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"10.1016\/j.hoc.2025.04.007_bib81","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/PAS.0000000000001196","article-title":"Novel PLAG1 gene rearrangement distinguishes a subset of uterine myxoid leiomyosarcoma from other uterine myxoid mesenchymal tumors","volume":"43","author":"Arias-Stella","year":"2019","journal-title":"Am J Surg Pathol"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858825000450?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858825000450?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T20:10:44Z","timestamp":1784319044000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858825000450"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":81,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S0889858825000450"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2025.04.007","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Leiomyosarcoma Therapeutic Approaches and Future Directions","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2025.04.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}